in the absence of a submission from the holder of the marketing authorisation:
daratumumab (Darzalex®) is not recommended for use within NHSScotland.
Indication under review: In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice617KB (PDF)
Medicine details
- Medicine name:
- daratumumab (Darzalex®)
- SMC ID:
- SMC2469
- Indication:
In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy.
- Pharmaceutical company
- Janssen-Cilag Ltd
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 March 2022